Mirum Pharmaceuticals, Inc. (MIRM) on Thursday said Health Canada has approved the tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). Following the announcement, the company's shares rose more than 5% in pre-market trading.ALGS is a rare genetic disorder that affects multiple organ systems, including the liver, where bile duct abnormalities can lead to cholestasis and severe itching, known as pruritus.Livmarli was previously approved in Canad ...

Core Insights - Three stocks in the health care sector are signaling potential warnings for momentum-focused investors as of February 2, 2026 [1] Group 1: Momentum Indicators - The Relative Strength Index (RSI) is a key momentum indicator that compares a stock's performance on days with price increases to days with price decreases, helping traders gauge short-term performance [2] - A stock is generally considered overbought when its RSI exceeds 70, indicating potential caution for investors [2] Group 2: Specific Stocks - Brookdale Senior Living Inc (NYSE:BKD) and Mirum Pharmaceuticals Inc (NASDAQ:MIRM) are highlighted as major overbought stocks in the health care sector [3] - Amicus Therapeutics has seen a significant stock price increase of approximately 139% over the past six months, with a recent RSI value of 80.4, indicating it is overbought [3] - The stock of Amicus Therapeutics closed at $14.29, slightly up by 0.1% on the last trading day, with a 52-week high of $14.38 [3]

Core Viewpoint - Mirum Pharmaceuticals is showing strong performance and growth potential, with shares more than doubling over the past year, but it is not yet consistently profitable [1][2]. Financial Performance - For the first nine months of 2025, Mirum generated $372.4 million in revenue, reflecting a year-over-year increase of 56.8% [3]. - The company reported a loss per share of $0.35 for this period, an improvement from a loss of $1.36 per share in the same period last year [3]. - In Q3 2025, Mirum achieved a net profit of $2.9 million, a significant turnaround from a net loss of $14.2 million in Q3 2024 [4]. Revenue Projections - Mirum expects to achieve $520 million in net product sales for the full 2025 fiscal year, indicating at least a 54.4% growth compared to 2024 [6]. - For 2026, the company is guiding for net sales between $630 million to $650 million, representing a midpoint growth of 23.1% compared to 2025 [6]. Strategic Acquisitions - The company recently acquired Bluejay Therapeutics for $620 million, which may negatively impact short-term profitability due to acquisition costs but is expected to enhance revenue and earnings in the long run [7]. Future Outlook - Mirum has key clinical catalysts that could positively impact its stock price and drive sales growth [8]. - Despite recent strong performance, there are concerns about limited upside potential and the timeline for achieving consistent profitability [8][9].

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is one of the 11 Best Stocks to Buy for Investment. On January 26, TheFly reported that H.C. Wainwright raised its price target on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) from $102 to $130 while maintaining its Buy rating. Swayampakula Ramakanth from H.C. Wainwright has increased the price target on MIRM twice in a span of two weeks. H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? Ramakanth’s price ta ...

The future looks bright for this high-flying biotech stock.Mirum Pharmaceuticals' (MIRM +2.79%) share price has more than doubled over the last 12 months. Is this biotech stock about to soar again in 2026? I think so – for two key reasons.At an inflection pointIn several important ways, Mirum is at an inflection point. It achieved positive cash flow from operations in 2025. That's a significant milestone for any small biotech company.NASDAQ : MIRMMirum PharmaceuticalsToday's Change( 2.79 %) $ 2.63Current Pr ...

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the best mid-cap growth stocks to buy right now. On January 13, Baird analyst Brian Skorney raised the firm’s price target on Mirum Pharmaceuticals to $95 from $81, while maintaining an Outperform rating. This revision came as the firm updated its valuation model after preliminary results delivered a beat-and-raise on earnings and guidance. The stronger-than-expected data provides a solid foundation heading into a high-activity year in 2026. Furthermore, ...

Core Insights - CorMedix (CRMD) and Mirum Pharmaceuticals (MIRM) attract investors in the rare-disease biotech sector due to smaller patient populations that can yield significant revenue through premium pricing and regulatory incentives [1] - Both companies benefit from clearer clinical endpoints and faster regulatory pathways, allowing quicker market entry compared to traditional drugs [1] CorMedix (CRMD) Overview - CorMedix's lead product, DefenCath, received FDA approval in late 2023 as the first antimicrobial catheter lock solution in the U.S., aimed at reducing catheter-related bloodstream infections in kidney failure patients [2] - DefenCath generated $167.6 million in net sales in the first nine months of 2025, indicating strong market adoption [7] - The company plans to expand DefenCath's label into total parenteral nutrition and has diversified its revenue through a $300 million acquisition of Melinta Therapeutics, adding seven approved therapies to its portfolio [7] - Despite initial success, CorMedix's future outlook is cautious, with 2026 revenue guidance of $300-$320 million and projected 2027 revenues of $100-$140 million, reflecting pricing pressures and limited growth [8][11] Mirum Pharmaceuticals (MIRM) Overview - Mirum's lead product, Livmarli, is approved for treating cholestatic pruritus in patients with Alagille syndrome and has seen a 70% year-over-year increase in net sales, reaching $161.4 million in the first nine months of 2025 [3][12] - The company has expanded its portfolio with a new tablet formulation of Livmarli and additional bile acid products from the acquisition of Travere Therapeutics, generating $118.8 million in the first nine months of 2025 [16] - MIRM's revenue guidance for 2026 is approximately $630-$650 million, supported by a broader product base and ongoing clinical studies for new therapies [16][28] Comparative Analysis - Both companies exhibit a similar risk-reward profile, but MIRM presents a clearer growth narrative with multiple revenue drivers, while CRMD's outlook is clouded by conservative guidance and reliance on a single product [4][9] - MIRM's shares have increased by 75.3% over the past six months, contrasting with CRMD's 38% decline, indicating market preference for MIRM's growth potential [23] - Valuation metrics show MIRM trading at a price/book ratio of 16.02, significantly higher than CRMD's 1.43, reflecting investor confidence in MIRM's growth prospects [24] Investment Recommendation - Mirum Pharmaceuticals is viewed as the better investment opportunity due to its strong sales growth, diversified revenue streams, and multiple growth levers, while CorMedix faces more uncertainty and competitive pressures [25][29]

Core Insights - Mirum Pharmaceuticals (MIRM) shares increased by 7.1% following the announcement of strong preliminary results for Q4 and full-year 2025, which boosted investor confidence [1][6] Financial Performance - Preliminary net product sales for Mirum in 2025 were approximately $520 million, exceeding the management's guidance of $500-$510 million provided in November 2025 [2][6] - Estimated net product sales for Livmarli were around $359 million for 2025, while Cholbam and Ctexli contributed approximately $161 million [4] - For Q4 2025, estimated net product sales were about $149 million, including $106 million from Livmarli and around $43 million from Cholbam and Ctexli [5] 2026 Sales Outlook - Mirum forecasts net product sales of approximately $630-$650 million for 2026 [6][7] - The company is conducting a phase III study for Livmarli aimed at treating pruritus in rare cholestatic conditions, with enrollment expected to complete in the first half of 2026 [7] Pipeline Developments - Mirum's lead pipeline candidate, volixibat, is under evaluation in two phase IIb studies for primary biliary cholangitis and primary sclerosing cholangitis, with top-line data from the VISTAS study anticipated in Q2 2026 [8] - A definitive agreement to acquire Bluejay Therapeutics was announced in December 2025, which will enhance Mirum's portfolio in rare liver diseases [9] - A phase II study has been initiated for MRM-3379, a PDE4D inhibitor targeting Fragile X syndrome [10]

PresentationGreat. Good morning, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing our 44th Annual Healthcare Conference this morning with Mirum. First, you're going to hear a presentation from the company and then we're going to go into a Q&A session. So for all of you in the room, if you do have a question, just raise your hand so someone can bring you a microphone for the webcast. And if you're listening online, you can submit questions to the portal, and I can read t ...

Summary of Mirum Pharmaceuticals FY Conference Call Company Overview - **Company**: Mirum Pharmaceuticals (NasdaqGM:MIRM) - **Focus**: Rare disease company delivering life-changing medicines to patients with rare diseases - **Key Products**: Livmarli, Volixibat, Chenodal, Cholbam, Brilovatug Financial Performance - **2025 Product Revenue**: Estimated at $520 million - **2026 Revenue Guidance**: Expected between $630 million and $650 million - **Potential Revenue from Pipeline**: Over $4 billion across current commercial and pipeline programs [3][25] Key Products and Pipeline Livmarli - **Indications**: Approved for Alagille syndrome and PFIC, with a third indication expected to read out later this year - **2025 Revenue**: $359 million, with strong growth driven by pediatric patient starts and label expansion into PFIC [8][30] - **Future Potential**: Estimated billion-plus potential opportunity [6][30] - **EXPAND Study**: Aiming for label expansion into other cholestatic pruritic indications, with top-line data expected in Q4 [10][12] Volixibat - **Indications**: Studied for PSC and PBC, targeting a significant unmet need in cholestatic pruritus [12][13] - **Market Size**: Approximately 30,000 patients with PSC, with two-thirds experiencing pruritus [13] - **Upcoming Data**: Top-line data from the VISTAS study expected next quarter, with NDA filing anticipated in the second half of the year [16][25] Brilovatug (Acquisition of BlueJ Therapeutics) - **Indication**: Targeting hepatitis delta, a rare co-infection with HBV - **Market Size**: Approximately 15,000 diagnosed and insured patients in the U.S., with potential for higher prevalence in other regions [22][48] - **Phase 2 Results**: Achieved 100% virologic response, with a 65%-82% response rate on FDA approval endpoints [23][47] - **Phase 3 Program**: AZURE studies currently enrolling, with top-line data expected in the second half of the year [24][25] Market Dynamics - **Livmarli**: Strong growth driven by increased awareness and diagnosis in adult PFIC settings, with a focus on genetic testing [9][28] - **Volixibat**: Positioned as the only potential therapy for PSC, with a significant market opportunity due to the lack of approved therapies [41][42] - **PBC Market**: More competitive with recent approvals of PPARs, but still presents opportunities for IBAT inhibitors [43] Commercial Strategy - **Geographic Focus**: Direct commercialization in North America and Western Europe, with partnerships in smaller countries [5] - **Field Expansion**: Plans to increase the U.S. field force by 30-40 people to target community physicians and GI specialists [44] Risks and Considerations - **Regulatory Risks**: Ongoing monitoring of clinical trial outcomes and regulatory approvals for pipeline products [2][25] - **Market Competition**: Need to navigate competitive landscapes, especially in the PBC market [42][43] Conclusion - Mirum Pharmaceuticals is positioned for significant growth with a strong pipeline and commercial strategy, focusing on rare diseases and addressing unmet medical needs in cholestatic conditions and hepatitis delta. The company anticipates pivotal data readouts in the coming year that could further enhance its market position and revenue potential [25][26].